We conducted a double-blind, placebo-controlled trail in which 40 patients who had undergone long-term therapy with benzodiazepines were switched to placebo or to diazepam in a dose approximately equivalent to their usual dose of the benzodiazepine; the dose of diazepam was then tapered during an eight-week period. Patients were assessed clinically and psychologically and had weekly sessions of behavioral therapy. The subjects who received placebo had more symptoms, assessed their symptoms as more severe, and stopped taking the study drug at a higher rate than those receiving the tapering doses of diazepam. The subjects in the placebo group also had symptoms shortly after being switched to placebo, whereas those in the diazepam group had symptoms much later. Some withdrawal symptoms were distinct from those of anxiety (e.g., tinnitus, involuntary movement, and perceptual changes). Withdrawal symptoms occurred earlier in patients who had received short-acting benzodiazepines than in those who had received long-acting benzodiazepines. Symptoms gradually disappeared over a four-week period in both the placebo and the diazepam groups. Serial determination of plasma benzodiazepine concentrations was a useful way to assess compliance, treatment outcome, and relapse during withdrawal. We conclude that a clinically important, mild, but distinct withdrawal syndrome occurs after discontinuation of long-term therapeutic use of benzodiazepines.
This article has been cited by other articles:
Kudoh, A., Takase, H., Takahira, Y., Takazawa, T.
(2004). Postoperative Confusion Increases in Elderly Long-Term Benzodiazepine Users. Anesth. Analg.
99: 1674-1678
[Abstract][Full Text]
Nutt, D. J.
(2003). Death and Dependence: Current Controversies over the Selective Serotonin Reuptake Inhibitors. J Psychopharmacol
17: 355-364
[Abstract]
Saito, M., Terao, Y., Fukusaki, M., Makita, T., Shibata, O., Sumikawa, K.
(2003). Sequential Use of Midazolam and Propofol for Long-Term Sedation in Postoperative Mechanically Ventilated Patients. Anesth. Analg.
96: 834-838
[Abstract][Full Text]
Lelas, S., Gerak, L. R., France, C. P.
(2000). Antagonism of the Discriminative Stimulus Effects of Positive gamma -Aminobutyric AcidA Modulators in Rhesus Monkeys Discriminating Midazolam. J. Pharmacol. Exp. Ther.
294: 902-908
[Abstract][Full Text]
Riedel, B. W., Lichstein, K. L., Peterson, B. A., Epperson, M. T., Means, M. K., Aguillard, R. N.
(1998). A Comparison of the Efficacy of Stimulus Control for Medicated and Nonmedicated Insomniacs. Behav Modif
22: 3-28
[Abstract]
Caley, C. F.
(1996). The Pharmacotherapy of Human Aggression: A Review. Journal of Pharmacy Practice
9: 133-143
[Abstract]
O'Sullivan, G. H., Swinson, R., Kuch, K., Marks, I. M., Basoglu, M., Noshirvani, H.
(1996). Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study. J Psychopharmacol
10: 101-109
[Abstract]
DuPont, R. L., DuPont, C. M.
(1994). The Treatment of Anxiety: Realistic Expectations and Risks Posed by Controlled Substances. J Law Med Ethics
22: 206-214
Shader, R. I., Greenblatt, D. J.
(1993). Use of Benzodiazepines in Anxiety Disorders. NEJM
328: 1398-1405
[Full Text]
Lader, M. H., Morton, S. V.
(1992). A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. J Psychopharmacol
6: 357-363
[Abstract]
Swantek, S. S., Grossberg, G. T., Neppe, V. M., Doubek, W. G., Martin, T., Bender, J. E.
(1991). The Use of Carbamazepine to Treat Benzodiazepine Withdrawal in a Geriatric Population. J Geriatr Psychiatry Neurol
4: 106-109
[Abstract]
Previous
